Authors: Tian Wang Zhaohui Chu Hao Lin Jingwei Jiang Xinli Zhou Xiaohua Liang
Publish Date: 2014/03/11
Volume: 41, Issue: 6, Pages: 4069-4076
Abstract
Recently the recruitment/migration of myeloid derived suppressor cells MDSCs to tumor microenvironment after chemotherapy has attracted much attention To determine the detailed mechanism for the responses of MDSCs to these chemotherapies we investigated the changes of galectin3 and MDSCs in response to cisplatin04 mg/kg 4 mg/kg treatment both in vivo and ex vivo In the process of cisplatin we assessed levels of galectin3 and MDSCs in the Lewis lung cancer LLC bearing mice using immunohistochemistry enzymelinked immunosorbent assay ELISA immunofluorence and flow cytometry FCM The expression and changes of galectin3 in the LLC cell line were detected by western blot immunofluorence and ELISA The ligand for galectin3 on MDSCs and the chemotaxis of galectin3 to MDSCs were confirmed using FCM and transwell Parallel increased level of galectin3 with the number of MDSCs in vivo was detected after cisplatin treatment LLC cells expressed galectin3 and cisplatin increased galectin3 level in the culture medium Furthermore MDSCs were detected to express CD98 the ligand of galectin3 and could be recruited by galectin3 Our results suggested that the elevated expression of gelectin3 in LLC tumor cells may contribute to the migration of MDSCs to the tumor microenvironment in response to cisplatin
Keywords: